Free Trial
→ Inside the Options Play With a High Historical Win Rate (From TradeWins) (Ad)tc pixel
NASDAQ:ALEC

Alector Q3 2026 Earnings Date & Estimates

Alector logo
$2.08 +0.06 (+2.97%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.07 -0.01 (-0.48%)
As of 10/9/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alector is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alector in Q3 2026

Alector is expected to post earnings of -$0.23 per share on revenue of $2.38 million. In the same quarter a year earlier Alector reported -$0.34 per share on revenue of $3.26 million. Alector last reported on August 6, 2026, posting -$0.21 per share and beating the -$0.2286 consensus estimate. Alector has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.23
Expected Revenue
$2.38 million
Prior-Year EPS
-$0.34
Prior-Year Revenue
$3.26 million
Expected Revenue Growth
-27.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.21 (Beat by +$0.0186)
Last Quarter Revenue
$3.32 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Alector Q3 2026 Earnings FAQ

Alector (NASDAQ:ALEC) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Alector's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alector to post earnings of -$0.23 per share for Q3 2026.

The consensus revenue estimate for Alector is $2.38 million for Q3 2026.

Alector Earnings Headlines

Morgan Stanley Remains a Sell on Alector (ALEC)
October 8 at 6:50 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ALEC/pressreleases/5001755/morgan-stanley-remains-a-sell-on-alector-alec/
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
October 7 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376831/0/en/alector-to-host-virtual-research-and-development-event-highlighting-wholly-owned-alector-brain-carrier-abc-enabled-pipeline.html
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
October 10 at 1:00 AM  |  Weiss Ratings (Ad)
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/roche-stocks-genentech-commits-100-194310973.html
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/alector-shares-sealing-1-27bn-105933343.html
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/optogenics-researchers-win-nobel-prize-135700905.html
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease.

Alector’s pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells. The program is being developed for frontotemporal dementia caused by progranulin gene mutations. The company has also pursued additional investigational programs targeting immune and neurological pathways relevant to neurodegenerative disorders.

Founded in 2013, Alector is headquartered in South San Francisco, California. The company was co-founded by Arnon Rosenthal, Ph.D., who has served as its chief executive officer, and entrepreneur Tillman Gerngross, Ph.D. Alector’s research and development activities are primarily focused on advancing potential treatments for patients in the United States and other international markets through clinical development and collaborations.

View Alector Profile
Earnings Tools